Solide Tumore
FOOTPATH
A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH, EudraCT Nummer: 2017-003496-54)
Indikation: Erstdiagnose Bauchspeicheldrüsenkrebs (Pankreskarzinom)
Ansprechpartner
SEPION
A multicenter phase I/II study of sequential epigenetic and immune targeting in combination with nab-Paclitaxel / Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (SEPION, EudraCT Nummer: 2017-001625-40)
Indikation: Erstdiagnose Bauchspeicheldrüsenkrebs (Pankreaskarzinom)
Ansprechpartner
BNT000-001
Epidemiological study to monitor study participants with resected Stage II (high risk) or Stage III colorectal cancer for circulating tumor DNA before, during and after their treatment with adjuvant chemotherapy (NCT04813627)
Indikation: Pat mit operiertem CRC Stadium II+RF/III hinweisen
(RF: T4, Grade >=3, clinical presentation with obstruction/perforation, histological signs of vascular or lymphatic or perineural invasion, less than 12 lymph nodes examined)
Ansprechpartner
BNT122-01
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (EudraCT Nummer 2020-000451-12)
Indikation: ctDNA positive Pat mit operiertem CRC Stadium II+RF/III
(RF: T4, Grade >=3, clinical presentation with obstruction/perforation, histological signs of vascular or lymphatic or perineural invasion, less than 12 lymph nodes examined)
Ansprechpartner
RAMTAS
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients (RAMTAS, EudraCT Nummer: 2017-004162-99)
Indikation: Metastasierter Darmkrebs nach Durchlaufen der Standardtherapie
Ansprechpartner
MK-4280A-007
A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280-007, EudraCT Nummer: 2021-001309-60)
Indikation: Metastasierter Darmkrebs nach Durchlaufen der StandardtherapieAnsprechpartner
MEN1611-02
Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens (MEN1611-02, EudraCT Nummer: 2019-003727-38 )
Indikation: Metastasierter Darmkrebs, PIK4CA-mutiert, nach Durchlaufen der StandardtherapieAnsprechpartner
FIRE-4
A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab (FIRE-4, EudraCT Nummer: 2014-003787-21)
Indikation: Metastasierter Darmkrebs, Drittlinientherapie, vorheriges Ansprechen auf FOLFIRI + anti-EGFR-InhibitorAnsprechpartner
FIRE 7
Impact of a Centralized Tumour Board on Secondary Intervention Rate in Patients With RAS Mutant Metastatic Colorectal Cancer After First-line Treatment With FOLFOXIRI Plus Bevacizumab (FIRE-7, NCT Identifier: NCT04852250)
Indikation: Erstdiagnose Darmkrebs, Evaluation Resektabilität nach 4 Zyklen FOLFOXIRI + Bevacizumab.
Ansprechpartner
FIRE 8
Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (FIRE-8, EudraCT Nummer: 2019-004223-20)
Indikation: Metastasierter Darmkrebs nach Durchlaufen der Standardtherapie
Ansprechpartner
FIRE 9
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer (FIRE-9, EudraCT Nummer: 2020-006144-18)
Indikation: Systemtherapie vs BSC nach Metastasenresektion beim Darmkrebs
Ansprechpartner
CA209-8HW
A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer (CA209-8HW, EudraCT Nummer: 2018-000040-26)
Indikation: Erstdiagnose Darmkrebs mit Mikrosatelliteninstabilität
Ansprechpartner
Dr. Danmei Zhang
ATOMIC
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC, Registry Identifier CTRP: NCI-2016-01417)
Indikation: Adjuvante Therapie (nach Operation) bei Darmkrebs mit einem DNA-Reparatur-Mechanismusdefekt
Ansprechpartner
Aktuell keine entitätsspezifischen Studien, siehe Studienoptionen unter Allgemeine Solide Tumore
AMG199-NIS
Nicht-interventionelle Biomarker-Studie zur molekularen Auswertung von konserviertem Tumorgewebe bei Patienten mit Magenkarzinom (AMG 199 201 80 293)
Indikation: Biomarkerstudie. Metastasierter Magen-, Bauchspeicheldrüsen-, und Darmkrebs nach Durchlaufen der Standardtherapie
Ansprechpartner
AMG 199
A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (AMG 199,, EudraCT Nummer: 2019-002708-42)
Indikation: Metastasierter Magen-, Bauchspeicheldrüsen-, und Darmkrebs nach Durchlaufen der Standardtherapie
Ansprechpartner
CUPISCO
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy (CUPISCO, EudraCT: 2017-003040-20)
Indikation: Erstdiagnose Cancer of Unknown Primary (Krebserkrankung mit unbekanntem Primärtumor)
Ansprechpartner
TAPISTRY
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Indikation: Biomarkerspezifische Therapie bei fortgeschrittenen soliden Tumoren, nach Durchlaufen der Entitätsspezifischen Standardtherapie
Ansprechpartner
TOP ART
A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies (TOP-ART, Study ID: NCT-2017-0417)
Indikation: fortgeschrittene solide Tumore mit einem DNA-Reparaturdefizit
Ansprechpartner
KEYVIBE-005 (MK-7684A-005)
A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005, EudraCT Nummer: 2021-001700-15)
Indikation: fortgeschrittene Tumore folgender Entitäten (Gebärmutterhalskrebs, Endometriumskarzinom, Kopf-Hals-Tumore, Gallengangstumore, Tumore der Speiseröhre und des gastroösophagealen Übergangs, Triple-negatives Mammakarzinom)
Ansprechpartner
Dr. Danmei Zhang
MB-CART20.1
Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma (MB-CART20.1, EudraCT Nummer: 2017-000120-10)
Indikation: CAR T Zelltherapie beim metastasierten malignem Melanom nach Durchschreiten der Standardtherapie
Ansprechpartner
Dr. Klara Dorman
Prof. Dr. Sebastian Theurich
LIBRETTO-531
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531; EudraCT Nummer: 2019-001978-28)
Indikation: RET-mutiertes medulläres Schilddrüsenkarzinom
Ansprechpartner
Dr. Danmei Zhang
Prof. Dr. Dr. Mathias Kroiß Prof. Dr. Christine Spitzweg